The future of companion DTx

Commercialization of DTx solutions as digital drug companions are starting to show promise as valuable routes to market differentiation. There are few drug-device combination products, propelled by COVID-19 and increased investment in DTx solutions in general. However, is there room for pharma companies to go further with DTx companion solutions? What bundling and labeling pathways are feasible? Although regulatory bodies have offered some guidance, the industry still needs clear and consistent development and launch requirements. But beyond regulatory concerns, what are the main challenges when bringing companion DTx to market (e.g. legal, data protection & privacy, Health IT integration, market acceptance, ROI requirements)? What goals will maximize the value of DTx companions (e.g therapy value proposition, improved health outcomes, value-based agreements, etc.)? Join this meeting to have an engaging conversation with other thought leaders about the future of companion DTx products.